GlassScriptPhysician profile
Tanja Morgan
NPI 1043587124
$1,636.40
in general payments reported to CMS, 2019-2025
25 companies · $68.40 in 2025
The $68.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $513 · 2022: $655 · 2023: $279 · 2024: $122 · 2025: $68.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.46 | 2021-2023 | |
| Pfizer INC. | $222.53 | 2021-2025 | |
| Novo Nordisk INC | $170.84 | 2021-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $114.56 | 2021-2024 | |
| Lilly USA, LLC | $107.52 | 2021-2023 | Mounjaro |
| Amgen INC. | $106.91 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $100.18 | 2021-2023 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.70 | 2022 | |
| Amarin Pharma, INC. | $57.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.40 | 2021 | |
| Astellas Pharma US INC | $29.52 | 2023 | Veozah |
| Esperion Therapeutics, INC. | $28.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.61 | 2021-2025 | Breztri |
| Merck Sharp & Dohme LLC | $28.16 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.40 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $16.93 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.88 | 2021 | |
| Exact Sciences Corporation | $16.83 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.82 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.23 | 2021 | |
| Antares Pharma, INC. | $13.21 | 2022 | |
| Philips North America LLC | $12.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.90 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanja Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.